The study shows the MSDA Test delivers an objective, quantifiable measure of inflammatory disease activity to distinguish true relapse from pseudoexacerbation, a common challenge in today’s standard ...
Study Published in Multiple Sclerosis Journal – Experimental, Translational and Clinical Reinforces Clinical Utility of Octave MSDA Test in Managing MS Octave Bioscience, Inc., a leading precision ...
The MarketWatch News Department was not involved in the creation of this content. Collaboration enables patients to access the Octave MSDA test at Quest's approximately 7,000 patient access sites ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Octave, a leading neuroscience precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, today ...
The Only Clinically Validated Multiple Sclerosis Multi-Analyte Test Proven to Deliver Clinically Meaningful Insights Is Now Available In All 50 States MENLO PARK, Calif.--(BUSINESS WIRE)-- Octave® ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Octave® Bioscience, Inc., a leading precision care company that delivers a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, ...
MENLO PARK, Calif., July 08, 2026--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial-stage precision neurology company pioneering a new standard for managing multiple sclerosis (MS) and other ...
Collaboration enables patients to access the Octave MSDA test at Quest’s approximately 7,000 patient access sites across the U.S. and establishes a pathway to introduce additional tests from Octave’s ...
ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. The study shows the MSDA Test delivers an objective, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results